Tagged Articles

malignacies 2 articles

European Union approves new combination treatment for type 2 diabetes

European Union drug regulators have approved a new combination pill to treat type 2 diabetes. Vokanamet combines the new diabetes drug Invokana with the standard treatment metformin. The new treatment is made by Johnson & Johnson and will be marketed in Europe by Janssen-Cliag International. The active ingredient in Invokana is canagliflozin, which is in a class of diabetes medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. These drugs are designed to help reduce blood sugar levels by preventing the reabsorption of glucose from the kidneys back into the blood, and allows glucose to be excreted in the urine. The U.S. ... Read More

Chron’s, colitis drug linked to deadly cancer

A fast-growing and deadly type of cancer has been reported in patients – in particular, adolescents and young adults – who are taking a type of medication used to treat Crohn’s disease and ulcerative colitis. The Food and Drug Administration (FDA) alerted doctors that a rare cancer of white blood cells known as Hepatosplenic T-Cell Lymphoma or HSTCL has been linked to medicines called tumor necrosis factors (TNF) blockers, as well as with azathioprine and/or mercaptopurine. TNF blockers include Remicade (infliximab), Enbrel (etancercept), Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab). HSTCL is an aggressive cancer that is usually fatal. ... Read More